BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer.

Cancer 2014 Aug 15;120(15):2316-24. Epub 2014 Apr 15.

Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York.

Background: BRAF mutations occur in 5% to 11% of patients with metastatic colorectal cancer (mCRC) and have been associated with poor prognosis. The current study was undertaken to determine the clinicopathologic characteristics, PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha) mutation frequency, and outcomes after metastasectomy in patients with BRAF-mutant mCRC.

Methods: Data from 1941 consecutive patients with mCRC who underwent KRAS/BRAF mutation testing between 2009 and 2012 at a single institution were identified to identify BRAF-mutant mCRC cases (92 cases). BRAF wild-type mCRC cases from 2011 (423 cases) served as a control group.

Results: BRAF-mutated mCRC was found to be significantly associated with older age at diagnosis, female sex, right-sided location, poorly differentiated morphology, and mucinous histology compared with wild-type cases. BRAF-mutant cases more frequently progressed from stage III disease (32% vs 17%; P = .003) and among those patients with stage III disease, T4 disease was more common (48% vs 27%; P = .05). PIK3CA was found to be co-mutated in 5% of BRAF-mutant tumors versus 17% of KRAS-mutant tumors (P < .01) and 4% of BRAF/KRAS wild-type cases. Patients with BRAF-mutated mCRC presented more frequently with peritoneal involvement (26% vs 14%; P < 0.01) and less frequently with liver-limited metastases (41% vs 63%; P < .01). Patients with BRAF-mutated mCRC were less likely to undergo metastasectomy (41% vs 26% at 2 years from diagnosis of metastatic disease; P < .01) and were found to have lower overall survival (P < .01) after metastasectomy.

Conclusions: BRAF-mutant mCRC is associated with worse clinical outcome. Patients with BRAF-mutant tumors more commonly develop peritoneal metastases, less frequently present with disease limited to the liver, and have shorter survival after metastasectomy compared with patients with BRAF wild-type tumors.

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.28729
Publisher Site
http://dx.doi.org/10.1002/cncr.28729DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4928876PMC
August 2014
30 Reads

Publication Analysis

Top Keywords

mcrc associated
8
stage iii
8
outcomes metastasectomy
8
patients metastatic
8
metastasectomy patients
8
metastatic colorectal
8
colorectal cancer
8
mcrc cases
8
iii disease
8
cases
6
mcrc
5
patients
5
disease 32%
4
single institution
4
2012 single
4
32% 17%
4
cases cases
4
institution identified
4
2009 2012
4
identify braf-mutant
4

References

(Supplied by CrossRef)
Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study
Samowitz et al.
Cancer Epidemiol Biomarkers Prev 2000
Cetuximab plus FOLFIRI: final data from the CRYSTAL study on the association of KRAS and BRAF biomarker status with treatment outcome [abstract]
Cutsem et al.
J Clin Oncol 2010

Similar Publications